Analysis and interpretation of the 2022 Global Cancer Statistics Report: cancer burden and epidemiological trends in China and the world

  • WU Qi ,
  • FAN Bonan ,
  • LI Yan
Expand
  • 1. Health and Wellness Industry Technology Research Institute,School of Foreign Studies,Yanshan University,Hebei Qinghuangdao 06600,China
    2. Department of Social Medicine and Health Management,School of Public Health,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China

Received date: 2024-10-26

  Accepted date: 2025-01-08

  Online published: 2025-07-11

Abstract

In February 2024, the International Agency for Research on Cancer (IARC) released the 2022 Global Cancer Statistics Report. In 2022, there were nearly 20 million new cancer cases and 9.7 million deaths. The report provides statistics on the incidence and mortality of 36 different types of cancer in 185 countries around the world, analyzing geographic, gender-based, and Human Development Index (HDI)-related differences. It also predicts the global burden of cancer disease by 2050. Demographic forecasts suggest that by 2050, the number of new cancer cases worldwide is expected to reach 35 million annually-an increase of 77% compared to 2022. Geographically, cancer incidence and mortality rates show significant regional disparities. In 2022, nearly half (49.2%) of the world's new cases and the majority (56.1%) of cancer deaths occurred in Asia. In terms of gender distribution, the overall cancer incidence and mortality rate among females were lower than those among males in 2022. With respect to HDI, the risk of developing cancer increases with higher HDI levels. In 2022, the top 5 newly diagnosed cancer cases worldwide are lung cancer, female breast cancer cancer, colorectal cancer, prostate cancer, gastric cancer in turn. There were nearly 2.5 million new lung cancer cases and over 1.8 million related deaths. Breast cancer in women accounted for 2.3 million new cases and nearly 670 000 deaths. Colorectal cancer, including anal cancer, had more than 1.9 million new cases and over 900 000 deaths. Prostate cancer recorded 1.5 million new cases and nearly 400 000 deaths. There were nearly 970 000 newly-diagnosed cases of gastric cancer and 660 000 related deaths. In China in 2022, lung cancer still ranks first in the cancer incidence spectrum in China, accounting for 22.0% of the total new cases of cancer in China. This proportion has further increased compared to 2018 data (17.9%), followed by colorectal cancer (10.7%), thyroid cancer (9.7%), liver cancer (7.6%), and gastric cancer (7.4%), which account for more than half of the total new cases in China (57.4%). This paper reviews the data sources and statistical methods used in the report, interprets the epidemiological trends of major cancer types, and analyzes the incidence and burden of major cancers prevalent in China, provi-ding an overview of their disease burden and epidemiological trends.

Cite this article

WU Qi , FAN Bonan , LI Yan . Analysis and interpretation of the 2022 Global Cancer Statistics Report: cancer burden and epidemiological trends in China and the world[J]. Journal of Diagnostics Concepts & Practice, 2025 , 24(02) : 135 -145 . DOI: 10.16150/j.1671-2870.2025.02.004

References

[1] BRAY F, LAVERSANNE M, WEIDERPASS E, SOERJOMATARAM I. The ever-increasing importance of cancer as a leading cause of premature death worldwide[J]. Cancer,2021,127(16):3029-3030.
[2] CHEN S, CAO Z, PRETTNER K, et al. Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050[J]. JAMA Oncol,2023,9(4):465-472.
[3] SOERJOMATARAM I, BRAY F. Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070[J]. Nat Rev Clin Oncol,2021,18(10):663-672.
[4] GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet,2022,400(10352):563-591.
[5] World Health Organization. "International agency for research on cancer". (2019)[EB/OL]. https://www.iarc.who.int.
[6] PARKIN D M, BRAY F, FERLAY J, et al. Estimating the world cancer burden: Globocan 2000[J]. Int J Cancer, 2001,94(2):153-156.
[7] FERLAY J, SHIN H R, BRAY F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer,2010,127(12):2893-2917.
[8] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: sources, met-hods and major patterns in GLOBOCAN 2012[J]. Int J Cancer,2015,136(5):E359-E386.
[9] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
[10] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
[11] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2024,74(3):229-263.
[12] FERLAY J, COLOMBET M, SOERJOMATARAM I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019,144(8):1941-1953.
[13] United Nations Development Programme. Human deve-lopment report 2021-2022. uncertainTimes, unsettled lives: shaping our futurein a transforming world[R/OL]. United Nations,2022. https://hdr.undp.org/content/human-development-report-2021-22.
[14] PARKIN D M. The evolution of the population-based cancer registry[J]. Nat Rev Cancer,2006,6(8):603-612.
[15] VAN TONG H, BRINDLEY P J, MEYER C G, et al. Parasite infection, carcinogenesis and human malignancy[J]. E Bio Medicine,2017,15:12-23.
[16] DE MARTEL C, FERLAY J, FRANCESCHI S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis[J]. Lancet Oncol, 2012,13(6):607-615.
[17] SCHMID V J, HELD L. Bayesian age-period-cohort mode-ling and prediction-BAMP[J]. J Stat Soft,2007,21(8):1-15.
Outlines

/